Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report)'s stock price rose 1.7% during trading on Thursday . The company traded as high as $54.14 and last traded at $53.74. Approximately 366,596 shares changed hands during trading, an increase of 94% from the average daily volume of 189,291 shares. The stock had previously closed at $52.83.
Gemini Therapeutics Trading Down 1.9 %
The company has a market capitalization of $2.26 billion, a PE ratio of -52.24 and a beta of -0.12. The business's fifty day moving average is $55.26 and its two-hundred day moving average is $56.08.
Gemini Therapeutics Company Profile
(
Get Free Report)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
Before you consider Gemini Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gemini Therapeutics wasn't on the list.
While Gemini Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
